GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were introduced for type 2 diabetes therapy nearly 10 years ago, among them short-acting compounds on the basis of the GLP-1-like peptide exendin-4 (exenatide and lixisenatide) and a long-acting GLP-1 RA based on the human GLP-1 sequence (liraglu...

Descripción completa

Detalles Bibliográficos
Autor principal: Gallwitz, Baptist
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2015
Materias:
Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819057/
https://www.ncbi.nlm.nih.gov/pubmed/29632562
http://dx.doi.org/10.17925/EE.2015.11.01.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819057/
https://www.ncbi.nlm.nih.gov/pubmed/29632562
http://dx.doi.org/10.17925/EE.2015.11.01.21

Ejemplares similares